Market Cap : 411.49 M | Enterprise Value : 497.16 M | PE Ratio : At Loss | PB Ratio : |
---|
NAS:HLVX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:HLVX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
HilleVax does not have enough data to calculate Piotroski F-Score.
The historical data trend for HilleVax's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HilleVax Semi-Annual Data | ||
Dec20 | Dec21 | |
Piotroski F-Score | - | - |
For the Biotechnology subindustry, HilleVax's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, HilleVax's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where HilleVax's Piotroski F-Score falls into.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Thank you for viewing the detailed overview of HilleVax's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.
Fhmls X, L.l.c. | 10 percent owner | 601 UNION STREET, SUITE 3200 TWO UNION SQUARE SEATTLE WA 98101 |
Dubin Gary | director | C/O HILLEVAX, INC. 75 STATE STREET, SUITE 100 - #9995 BOSTON MA 02109 |
Borkowski Astrid | officer: Chief Medical Officer | C/O HILLEVAX, INC. 75 STATE STREET, SUITE 100 - #9995 BOSTON MA 02109 |
Sepulveda Jaime | director | C/O HILLEVAX INC. 75 STATE STREET 100 - #9995 BOSTON MA 02109 |
Takeda Vaccines, Inc. | 10 percent owner | 75 SIDNEY STREET CAMBRIDGE MA 02139 |
Chu Shelley | director | ONE WINTHROP SQUARE SUITE 400 BOSTON MA 02110 |
Silbermann Susan Michele | director | C/O LIANBIO 103 CARNEGIE CENTER DRIVE, SUITE 215 PRINCETON NJ 08540 |
Fhmls X, L.p. | 10 percent owner | 601 UNION STREET, SUITE 3200 TWO UNION SQUARE SEATTLE WA 98101 |
Frazier Life Sciences X, L.p. | 10 percent owner | 601 UNION STREET, SUITE 3200 TWO UNION SQUARE SEATTLE WA 98101 |
Gerberding Julie L. | director | 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033 |
Kohli Aditya | director, officer: Chief Operating Officer | C/O PHATHOM PHARMACEUTICALS, INC. 2150 E. LAKE COOK ROAD, SUITE 800 BUFFALO GROVE IL 60089 |
Socks David A | officer: CFO & Chief Business Officer | C/O CADENCE PHARMACEUTICALS, INC. 12481 HIGH BLUFF DRIVE, SUITE 200 SAN DIEGO CA 92130 |
Takeda Pharmaceutical Co Ltd | 10 percent owner | 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU TOKYO M0 103-8668 |
Hershberg Robert | director, officer: President and CEO | 3005 FIRST AVENUE SEATTLE WA 98121 |
Topper James N | 10 percent owner | 550 HAMILTON AVENUE, SUITE 100 PALO ALTO CA 94301 |
From GuruFocus
Other Sources
By tipranks.com 2022-05-25